Skip to content

Study · Not a test of the peptide alone · 1993

3 results

Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.

Clemons RD, Kappy MS, Stuart TE, Perelman AH, Hoekstra FT

American journal of diseases of children (1960)1 Jun 1993Cited by 30 (Europe PMC)

PMID8506834 (opens in a new tab)DOI10.1001/archpedi.1993.02160300059023 (opens in a new tab)PepBankPUB-08506834
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Gonadorelin (GnRH, LHRH).

  1. 01HumanNot a test of Gonadorelin (GnRH, LHRH) aloneNon-randomized trialOther

    In girls with central precocious puberty, mean peak FSH response to a gonadorelin test fell during leuprolide depot treatment and stayed suppressed.

    In plain wordsIn girls with early puberty, the leuprolide drug lowered the FSH response to a gonadorelin test. Gonadorelin was a test tool here.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    DecreaseFSH response to gonadorelin test during leuprolide depot
    Study

    n = 10

    Comparator
    Before treatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Measurements

    mean peak FSH response
    21.8 IU/L
    before treatment
    mean peak FSH response
    2.4 IU/L
    after initial dose

    Source sentences

    Summary
    Mean peak serum concentrations of follicle-stimulating and luteinizing hormone responses to gonadorelin testing decreased significantly after the initial dose (from 21.8 +/- 4.5 [+/- SEM] to 2.4 +/- 0.2 IU/L for follicle-stimulating hormone and from 50.1 +/- 11.2 to 5.0 +/- 0.8 IU/L for luteinizing…
    2 context sentences
    Summary · context
    Children with documented central precocious puberty were treated with Lupron Depot for 1.6 to 3.5 years.
    Summary · context
    Ten girls with central precocious puberty defined as pubertal maturation statistically advanced for age combined with a pubertal gonadotropin response to gonadorelin testing.

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

  2. 02HumanNot a test of Gonadorelin (GnRH, LHRH) aloneNon-randomized trialOther

    In girls with central precocious puberty, mean peak LH response to a gonadorelin test fell during leuprolide depot treatment and stayed suppressed.

    In plain wordsIn girls with early puberty, the leuprolide drug lowered the LH response to a gonadorelin test. Gonadorelin was a test tool here.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    DecreaseLH response to gonadorelin test during leuprolide depot
    Study

    n = 10

    Comparator
    Before treatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Measurements

    mean peak LH response
    50.1 IU/L
    before treatment
    mean peak LH response
    5 IU/L
    after initial dose

    Source sentences

    Summary
    Mean peak serum concentrations of follicle-stimulating and luteinizing hormone responses to gonadorelin testing decreased significantly after the initial dose (from 21.8 +/- 4.5 [+/- SEM] to 2.4 +/- 0.2 IU/L for follicle-stimulating hormone and from 50.1 +/- 11.2 to 5.0 +/- 0.8 IU/L for luteinizing…
    2 context sentences
    Summary · context
    Children with documented central precocious puberty were treated with Lupron Depot for 1.6 to 3.5 years.
    Summary · context
    Ten girls with central precocious puberty defined as pubertal maturation statistically advanced for age combined with a pubertal gonadotropin response to gonadorelin testing.

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

  3. 03HumanNot a test of Gonadorelin (GnRH, LHRH) aloneNon-randomized trialOther

    In girls with central precocious puberty who finished leuprolide depot treatment, pubertal gonadotropin responses to gonadorelin testing returned within 2 to 6 months.

    In plain wordsIn girls with early puberty who finished leuprolide treatment, hormone responses to a gonadorelin test returned to puberty levels within 2 to 6 months.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    IncreaseReturn of gonadorelin test response after treatment stopped
    Study

    n: not reported in source

    Comparator
    During treatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Girls who completed their course of treatment had pubertal gonadotropin responses to gonadorelin testing within 2 to 6 months, and menarche within the first year if skeletal maturation reached 13.0 to 13.5 years.
    2 context sentences
    Summary · context
    Children with documented central precocious puberty were treated with Lupron Depot for 1.6 to 3.5 years.
    Summary · context
    Ten girls with central precocious puberty defined as pubertal maturation statistically advanced for age combined with a pubertal gonadotropin response to gonadorelin testing.

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.